ALEMBIC PHARMA LTD

Alembic Pharmaceuticals Limited held its Q1 FY27 Earnings Conference Call on August 4, 2026, where management reported a strong start to the year with consolidated revenue growth of 26% year-on-year, driven by broad-based growth across all major businesses. The India branded business grew by 7%, while international generics and the API business saw growth of 37% and 33%, respectively. Management highlighted the strength of the U.S. generics business, which grew by 49% year-on-year, supported by volume growth and new product launches. The company launched seven products during the quarter and received ten approvals. Management set a goal for the U.S. generics business to grow in the mid to high teens for FY27, while maintaining investments in R&D and manufacturing capabilities. The EBITDA margin was reported at 16%, with a 21% year-on-year growth in EBITDA. Management expressed confidence in the business's growth trajectory and strategic investments.

Management emphasized strong growth and strategic execution across various business segments.